New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 13, 2014
19:16 EDTNNA, PHMD, LOGM, VSI, GNC, GSK, LCAV, CLF, A, WTW, ARNA, CRAY, Z, TRLAOn The Fly: After Hours Movers
UP AFTER EARNINGS: Cliffs Natural (CLF), up 6.4% after reporting better-than-expected earnings and announcing it promoted Gary Halverson, formerly its president and COO, to president and CEO... LogMeln (LOGM), up 16%... Cray (CRAY), up 9.7%. ALSO HIGHER: LCA Vision (LCAV), up 29% after announcing an agreement to be acquired by PhotoMedex (PHMD) for $5.37 per share. Shares of PhotoMedex were little changed following the announcement... Arena Pharmaceuticals (ARNA), up 1.8% after the Daily Mail said GlaxoSmithKline (GSK) could be interested in a deal for the company. DOWN AFTER EARNINGS: Weight Watchers (WTW), down 20% after fourth quarter profit missed expectations and the company sharply cut its fiscal 2014 earnings outlook... GNC Holdings (GNC), down 15.7%... Trulia (TRLA), down 15.2%... Agilent (A), down 6%. ALSO LOWER: Vitamin Shoppe (VSI), down 8.5% after its vitamin retailing peer GNC reported disappointing fourth quarter sales and cut its fiscal 2014 outlook... Zillow (Z), down 3% after online real estate peer Trulia's quarterly report disappointed... Navios Maritime Acquisition (NNA), down 8.4% after filing to sell 12M shares of common stock.
News For WTW;GNC;TRLA;A;VSI;Z;CLF;LOGM;CRAY;LCAV;PHMD;ARNA;GSK;NNA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
May 12, 2015
16:35 EDTZZillow Group backs FY15 pro forma revenue view $690M, consensus $669.84M
Subscribe for More Information
15:00 EDTNNANotable companies reporting before tomorrow's open
Subscribe for More Information
15:00 EDTZNotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include McKesson (MCK), consensus $2.75... Zillow (Z), consensus (12c)... GoDaddy (GDDY), consensus 35c... RSP Permian (RSPP), consensus 17c... Parsley Energy (PE), consensus 0c... Vivint Solar (VSLR), consensus (38c)... New Relic (NEWR), consensus (25c)... Hortonworks (HDP), consensus (86c)... SunOpta (STKL), consensus 7c... OPOWER (OPWR), consensus (16c)... JP Energy Partners (JPEP), consensus (4c)... TubeMogul (TUBE), consensus (18c)... Ducommun (DCO), consensus 30c.
14:19 EDTZZillow Group May 93 straddle priced for 8% movement into Q1
10:16 EDTWTWOptions with decreasing implied volatility
Options with decreasing implied volatility: NDLS WTW FUEL AOL LC NLNK ZU CYBR ARWR HZNP
08:07 EDTZSunTrust to hold a conference
Subscribe for More Information
08:05 EDTZZillow Group signs 105 new multiple listing services in the past six weeks
Zillow Group announced that Zillow and Trulia have signed 105 new agreements with multiple listing services in the past six weeks. In total, Zillow Group has signed 235 new agreements with MLSs since January 2015.
06:02 EDTGSKGSK CEO cites 'poor choices' in rivals' M&A deals, Financial Times reports
Subscribe for More Information
May 11, 2015
19:15 EDTARNAOn The Fly: After Hours Movers
Subscribe for More Information
16:41 EDTARNAArena Pharmaceuticals reports Q1 EPS (10c), consensus (14c)
Subscribe for More Information
16:22 EDTARNAArena Pharmaceuticals enters collaboration with Roivant Sciences
Arena Pharmaceuticals announced that its subsidiary, Arena Pharmaceuticals GmbH, and Roivant Sciences Ltd., have entered into a Development, Marketing and Supply Agreement for nelotanserin, Arena's internally discovered inverse agonist of the 5-HT2A receptor. The agreement grants Roivant exclusive worldwide rights to develop and commercialize nelotanserin. Nelotanserin has been studied to date in multiple clinical trials involving over 900 subjects. Roivant intends to initiate additional Phase 2 clinical trials for the treatment of behavioral and neuropsychiatric disturbances, including psychoses, in patients with dementia and other neurological diseases. In addition, Roivant may pursue the development of nelotanserin for other neuropsychiatric disorders. Roivant will be responsible for funding the development and commercialization of nelotanserin. Under the agreement, Arena will manufacture clinical supply and commercial product to sell to Roivant. Arena will receive a $4.0M upfront payment and is eligible to receive $41.5M in regulatory and development milestone payments. Arena is also eligible to receive 15% of net sales of nelotanserin in exchange for the manufacture and supply of finished commercial drug product, and up to a total of $60.0M in one-time purchase price adjustment payments tied to certain commercial sales milestones.
15:54 EDTGSKGlaxo CEO defends strategy, warns of risks of chasing higher prices, FT says
GlaxoSmithKline (GSK) CEO Andrew Witty defends the company's shift in focus from high-priced prescription drugs to higher volume, but lower priced, products, warning that chasing ever-higher prices risks undermining the industry and may create "its own tension that leads to some kind of change,” reported Financial Times, citing an interview. Witty acknowledges the company's asset swap with Novartis (NVS) opens the door to a potential break up, but argues there are benefits to keeping pharmaceuticals, vaccines and consumer goods together and there would be “no logic” in a split at this early time after the Novartis deal, the report added. Reference Link
11:23 EDTPHMDPhotoMedex reports Q1 EPS (5c), one estimate (5c)
Reports Q1 revenue $28.1M, may not compare to two estimates $68.51M.
10:38 EDTLOGMLogMeln management to meet with Piper Jaffray
Subscribe for More Information
10:30 EDTZWellington reports 10.86% passive stake in Zillow Group
Subscribe for More Information
10:17 EDTWTWOptions with decreasing implied volatility
Subscribe for More Information
09:59 EDTZOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Alcatel-Lucent (ALU) upgraded to Outperform from Neutral at Exane BNP Paribas... Caterpillar (CAT) upgraded to Outperform at Baird... Cisco (CSCO) upgraded to Outperform with $36 target at Pacific Crest... Evolution Petroleum (EPM) upgraded to Outperform from Market Perform at Northland... Hecla Mining (HL) upgraded on hedging discipline at Roth Capital... Joy Global (JOY) upgraded to Outperform from Neutral at Baird... Monster Beverage (MNST) upgraded to Buy from Neutral at Citigroup... Nokia (NOK) upgraded to Outperform from Neutral at Exane BNP Paribas... On Deck Capital (ONDK) upgraded to Neutral from Sell at Sterne Agee CRT... Royal Caribbean (RCL) upgraded to Outperform from Neutral at Wedbush... SMC (SMECF) upgraded to Buy from Neutral at Goldman... Sally Beauty (SBH) upgraded to Outperform from Market Perform at Raymond James... Southwestern Energy (SWN) upgraded to Overweight from Equal Weight at Barclays... Sprouts Farmers Markets (SFM) upgraded to Outperform at BMO Capital... Suburban Propane (SPH) upgraded on positive outlook at Stifel... Suffolk Bancorp (SUBK) upgraded to Outperform from Market Perform at Keefe Bruyette... Syngenta (SYT) upgraded to Buy from Neutral at UBS... Triumph Group (TGI) upgraded to Outperform from Sector Perform at RBC Capital... United Natural Foods (UNFI) upgraded to Overweight from Equal Weight at Stephens... Web.com (WWWW) upgraded to Buy from Hold at Deutsche Bank... Zillow Group (Z) upgraded to Buy from Neutral at SunTrust.
07:41 EDTZZillow May volatility elevated at 72 into Q1 and outlook
Subscribe for More Information
07:26 EDTZZillow Group upgraded to Buy from Neutral at SunTrust
Subscribe for More Information
05:58 EDTGSKUNC, GlaxoSmithKline create dedicated HIV Cure center
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use